Acquiring Company
Tempest Therapeutics
Acquired Company
Factor Bioscience
San FranciscoCambridgeBiotechnologyHealthcareHealth CareTherapeuticsBiopharmaBiotechnologyHealth CareDescription
Tempest Therapeutics, Inc. has successfully closed an all-stock acquisition of dual-targeting CAR-T programs from Factor Bioscience. The acquisition enhances Tempest's portfolio with advanced clinical-stage products and extends its operational runway into mid-2027. This transaction is expected to support multiple value-generating milestones in the near future.
Fundz sees it the moment Tempest Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Factor Bioscience?
Factor Bioscience was acquired by Tempest Therapeutics, based in San Francisco. The deal was reported on February 4, 2026. Tempest Therapeutics is a development-stage biotechnology company. Tempest Therapeutics is publicly traded (TPST) and operates in Biotechnology.
When did Tempest Therapeutics acquire Factor Bioscience?
Tempest Therapeutics's acquisition of Factor Bioscience was reported on February 4, 2026. Tempest Therapeutics, Inc. has successfully closed an all-stock acquisition of dual-targeting CAR-T programs from Factor Bioscience. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Factor Bioscience do?
Factor Bioscience was founded to pioneer new methods for controlling gene expression and cell fate. The company innovates across mRNA, gene editing, cell reprogramming, and nucleic acid delivery. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.